Agios Pharmaceuticals Inc. (AGIO)
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
Agios Pharma Stock: A Buy After FDA Approves Aqvesme
Agios Pharmaceuticals upgraded to buy (market perform) after FDA approval of Aqvesme for Alpha- or Beta-Thalassemia, despite boxed warning for liver injury. AGIO's commercial upside from thalassemia is capped, with peak sales estimates around $500M, insufficient alone for profitability; SCD approval remains a major potential catalyst. AGIO maintains a strong cash position of $1.3B versus $101M in liabilities, providing ample runway for commercialization and further development.
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label
Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
Shares of Agios Pharmaceuticals jumped nearly 12% premarket on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date
AGIO faces uncertainty as the FDA misses its Dec. 7 deadline related to the sNDA for Pyrukynd in thalassemia and offers no new timeline.
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript
Agios Pharmaceuticals, Inc. ( AGIO ) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease November 19, 2025 8:00 AM EST Company Participants Morgan Sanford Brian Goff - CEO & Director Sarah Gheuens - Chief Medical Officer and Head of Research & Development Tsveta Milanova - Chief Commercial Officer Conference Call Participants Biree Andemariam Eric Schmidt - Cantor Fitzgerald & Co., Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Ellen Horste - TD Cowen, Research Division Alec Stranahan - BofA Securities, Research Division Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Luca Issi - RBC Capital Markets, Research Division Presentation Operator Good morning, and welcome to the Agios Pharmaceuticals Investor Conference Call and Webcast.
Agios Pharma reports mixed results in late-stage study for sickle cell disease drug
Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction in pain crises.
Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones
Agios Pharmaceuticals delivered strong Q3'25 results, with revenue up 44% year-over-year and continued momentum in its rare-disease pipeline. AGIO's key catalysts include the FDA decision on Pyrukynd's thalassemia sNDA in December 2025 and topline data from the 'RISE UP' sickle cell trial. Despite premium valuation, the company maintains a robust balance sheet and is positioned for significant growth if regulatory approvals and market expansion materialize.
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
